# ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects

> **NCT05668429** · PHASE1 · COMPLETED · sponsor: **Scynexis, Inc.** · enrollment: 6 (actual)

## Conditions studied

- Fungal Disease

## Interventions

- **DRUG:** Ibrexafungerp

## Key facts

- **NCT ID:** NCT05668429
- **Lead sponsor:** Scynexis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-14
- **Primary completion:** 2023-01-28
- **Final completion:** 2023-01-28
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2023-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05668429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05668429, "ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05668429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*